Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8506427 | 0.76 | MDM2 (0.59) | — | |
| SCHEMBL4552391 | 0.75 | AKR1C3 (0.46) | GSRAKR1C3GRIN2BPTGS2GRM4 | |
| SCHEMBL8049079 | 0.74 | ENPP2 (0.50) | GSRAKR1C3PTGS2ENPP2 | |
| SCHEMBL15556865 | 0.73 | GSR (0.59) | GSRAKR1C3GRIN2BPTGS2ENPP2 | |
| SCHEMBL8722500 | 0.73 | ENPP2 (0.48) | GSRAKR1C3PTGS2ENPP2 | |
| SCHEMBL28427675 | 0.73 | GSK3B (0.53) | GSRAKR1C3PTGS2ENPP2 | |
| SCHEMBL8071790 | 0.72 | GSR (0.46) | GSRAKR1C3PTGS2ENPP2 | |
| SCHEMBL6510946 | 0.72 | SRC (0.50) | AKR1C3PTGS2 | |
| SCHEMBL34837 | 0.72 | CA2 (0.61) | GSRAKR1C3PTGS2ENPP2 | |
| Hydrochloric Acid SCHEMBL15465891 | 0.72 | GSR (0.60) | GSRAKR1C3GRIN2BPTGS2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638630-B2 | Very Late Antigen-4 dependent inflammatory disease; asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders, autoimmune disorders, or atherosclerosis, inflammatory skin disorder; methyl 3-[2-(2,6-dichlorophenyl)-6-quinolinyl]-2-hydroxy-2-propenoate | UCB PHARMA S.A. (BE) | 2009-12-29 | — | — | US | disclosed |
| US-20080064720-A1 | 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors | UCB, S.A. (BE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064720-A1 | 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors | VCAM1, HRH4, LTA4H | GSR 4751/4885AKR1C3 3272/4885GRIN2B 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.